GAITHERSBURG, Md.--(BUSINESS WIRE)--Gene Logic Inc. (NASDAQ: GLGC) announced today that GL1001, the company’s clinical-stage drug candidate, showed indications of efficacy at relevant doses in in vivo testing for inflammatory bowel disease (IBD). Based on the in vivo test results and market opportunities in IBD, the Company is seeking a partner for the clinical development of GL1001.
